• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

亚阈值二极管微脉冲激光与传统激光光凝单药治疗或联合抗 VEGF 治疗糖尿病黄斑水肿的比较:贝叶斯网状 Meta 分析。

Subthreshold diode micropulse laser versus conventional laser photocoagulation monotherapy or combined with anti-VEGF therapy for diabetic macular edema: A Bayesian network meta-analysis.

机构信息

Postdoctoral Research Station of Medicine, School of Medicine, Tongji University, Shanghai, China.

Department of Clinic Medicine, Anhui Medical University, Hefei, China.

出版信息

Biomed Pharmacother. 2018 Jan;97:293-299. doi: 10.1016/j.biopha.2017.10.078. Epub 2017 Nov 6.

DOI:10.1016/j.biopha.2017.10.078
PMID:29091878
Abstract

AIMS

To assess the effects of laser photocoagulation as monotherapy or adjuvant therapy for the treatment of DME.

METHODS

A search of the Cochrane Library, Pubmed, Embase, and the clinicaltrial.gov registry for randomized clinical trials comparing any two treatments of interest (SDMLP monotherapy, CLP monotherapy, CLP plus anti-VEGF therapy) was performed. Data were collected and pooled by Bayesian network meta-analyses which accounts for both direct and indirect comparisons. The primary outcome was the mean change in best-corrected visual acuity measured by the logarithm of the minimal angle of resolution units. The secondary outcome was the mean change in central macular thickness from baseline to month 12.

RESULTS

Ranibizumab therapy combined with CLP was more effective than SDMLP alone (MD, -0.396; 95% CrI, -0.746 to -0.062) and CLP alone (MD, -0.621; 95% CrI, -0.823 to -0.431). There was no apparent difference of efficacy between SDMLP alone and CLP alone (MD, -0.225; 95% CrI, -0.501 to 0.058). There was no apparent difference of efficacy between SDMLP alone and Bevacizumab therapy combined with CLP (MD, -0.003, 95% CrI, -0.815 to 0.805).

CONCLUSION

There was no apparent difference on improving vision between SDMLP monotherapy and CLP monotherapy. The most effective treatment in the network was ranibizumab therapy combined with CLP followed by SDMLP monotherapy, Bevacizumab therapy combined with CLP, and CLP monotherapy in rank order.

摘要

目的

评估激光光凝作为单一疗法或辅助疗法治疗 DME 的效果。

方法

对 Cochrane 图书馆、Pubmed、Embase 和 clinicaltrial.gov 注册中心进行了检索,以查找比较任何两种治疗方法(SDMLP 单一疗法、CLP 单一疗法、CLP 联合抗 VEGF 治疗)的随机临床试验。通过贝叶斯网络荟萃分析收集和汇总数据,该分析同时考虑了直接和间接比较。主要结局是通过最小角分辨率单位对数测量的最佳矫正视力的平均变化。次要结局是从基线到第 12 个月中央黄斑厚度的平均变化。

结果

雷珠单抗联合 CLP 治疗比 SDMLP 单一疗法(MD,-0.396;95% CrI,-0.746 至-0.062)和 CLP 单一疗法(MD,-0.621;95% CrI,-0.823 至-0.431)更有效。SDMLP 单一疗法和 CLP 单一疗法的疗效差异不明显(MD,-0.225;95% CrI,-0.501 至 0.058)。SDMLP 单一疗法和贝伐单抗联合 CLP 治疗的疗效差异也不明显(MD,-0.003,95% CrI,-0.815 至 0.805)。

结论

SDMLP 单一疗法和 CLP 单一疗法在改善视力方面没有明显差异。网络中最有效的治疗方法是雷珠单抗联合 CLP 治疗,其次是 SDMLP 单一疗法、贝伐单抗联合 CLP 治疗和 CLP 单一疗法。

相似文献

1
Subthreshold diode micropulse laser versus conventional laser photocoagulation monotherapy or combined with anti-VEGF therapy for diabetic macular edema: A Bayesian network meta-analysis.亚阈值二极管微脉冲激光与传统激光光凝单药治疗或联合抗 VEGF 治疗糖尿病黄斑水肿的比较:贝叶斯网状 Meta 分析。
Biomed Pharmacother. 2018 Jan;97:293-299. doi: 10.1016/j.biopha.2017.10.078. Epub 2017 Nov 6.
2
Anti-vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema.抗血管内皮生长因子联合玻璃体内注射类固醇治疗糖尿病性黄斑水肿。
Cochrane Database Syst Rev. 2018 Apr 18;4(4):CD011599. doi: 10.1002/14651858.CD011599.pub2.
3
Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis.抗血管内皮生长因子治疗糖尿病性黄斑水肿:一项网状Meta分析。
Cochrane Database Syst Rev. 2017 Jun 22;6(6):CD007419. doi: 10.1002/14651858.CD007419.pub5.
4
Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis.抗血管内皮生长因子治疗糖尿病性黄斑水肿:一项网状Meta分析。
Cochrane Database Syst Rev. 2023 Jun 27;2023(6):CD007419. doi: 10.1002/14651858.CD007419.pub7.
5
Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema.采用抗血管内皮生长因子疗法治疗糖尿病性黄斑水肿的抗血管生成治疗
Cochrane Database Syst Rev. 2012 Dec 12;12:CD007419. doi: 10.1002/14651858.CD007419.pub3.
6
Anti-VEGF drugs compared with laser photocoagulation for the treatment of proliferative diabetic retinopathy: a systematic review and individual participant data meta-analysis.抗血管内皮生长因子药物与激光光凝术治疗增殖性糖尿病视网膜病变的比较:一项系统评价和个体参与者数据荟萃分析
Health Technol Assess. 2025 Apr 2:1-75. doi: 10.3310/MJYP6578.
7
Anti-VEGF drugs compared with laser photocoagulation for the treatment of diabetic retinopathy: a systematic review and meta-analysis.抗血管内皮生长因子药物与激光光凝术治疗糖尿病性视网膜病变的比较:一项系统评价和荟萃分析。
Health Technol Assess. 2024 Dec 11:1-71. doi: 10.3310/PCGV5709.
8
Anti-vascular endothelial growth factor for diabetic macular oedema.抗血管内皮生长因子治疗糖尿病性黄斑水肿
Cochrane Database Syst Rev. 2014 Oct 24(10):CD007419. doi: 10.1002/14651858.CD007419.pub4.
9
Anti-vascular endothelial growth factor for choroidal neovascularisation in people with pathological myopia.抗血管内皮生长因子用于病理性近视患者脉络膜新生血管化的治疗
Cochrane Database Syst Rev. 2016 Dec 15;12(12):CD011160. doi: 10.1002/14651858.CD011160.pub2.
10
Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion.抗血管内皮生长因子治疗视网膜分支静脉阻塞继发的黄斑水肿。
Cochrane Database Syst Rev. 2013 Jan 31(1):CD009510. doi: 10.1002/14651858.CD009510.pub2.

引用本文的文献

1
Persistent Diabetic Macular Edema: A Comprehensive Review of Current Treatments and Emerging Therapeutic Options.持续性糖尿病黄斑水肿:当前治疗方法及新兴治疗选择的全面综述
J Curr Ophthalmol. 2025 Jun 5;36(3):229-241. doi: 10.4103/joco.joco_133_24. eCollection 2024 Jul-Sep.
2
Settings and Clinical Applications of Subthreshold Micropulse Laser Therapy: A Review.阈下微脉冲激光治疗的设置与临床应用:综述
J Clin Med. 2024 Sep 26;13(19):5729. doi: 10.3390/jcm13195729.
3
Subthreshold micropulse diode laser treatment in diabetic macular edema: biological impact, therapeutic effects, and safety.
亚阈值微脉冲二极管激光治疗糖尿病性黄斑水肿:生物学影响、治疗效果和安全性。
Int Ophthalmol. 2024 Feb 3;44(1):3. doi: 10.1007/s10792-024-02973-6.
4
Intravitreal anti-vascular endothelial growth factor, laser photocoagulation, or combined therapy for diabetic macular edema: A systematic review and network meta-analysis.玻璃体内抗血管内皮生长因子、激光光凝或联合治疗糖尿病性黄斑水肿:系统评价和网络荟萃分析。
Front Endocrinol (Lausanne). 2023 Feb 2;14:1096105. doi: 10.3389/fendo.2023.1096105. eCollection 2023.
5
Diabetic macular edema treatment with subthreshold micropulse laser - five-year long monitoring.阈下微脉冲激光治疗糖尿病性黄斑水肿——五年长期监测
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2023 Mar;167(1):74-79. doi: 10.5507/bp.2022.055. Epub 2023 Jan 9.
6
Subthreshold Micropulse Laser for Diabetic Macular Edema: A Review.阈下微脉冲激光治疗糖尿病性黄斑水肿:综述
J Clin Med. 2022 Dec 29;12(1):274. doi: 10.3390/jcm12010274.
7
Standard threshold laser versus subthreshold micropulse laser for adults with diabetic macular oedema: the DIAMONDS non-inferiority RCT.标准阈值激光与亚阈值微脉冲激光治疗成人糖尿病性黄斑水肿:DIAMONDS 非劣效性 RCT。
Health Technol Assess. 2022 Dec;26(50):1-86. doi: 10.3310/SZKI2484.
8
Epidemiology of Treated Diabetes Ocular Complications in France 2008-2018-The LANDSCAPE French Nationwide Study.2008 - 2018年法国糖尿病眼部并发症治疗的流行病学——法国全国性LANDSCAPE研究
Pharmaceutics. 2022 Oct 28;14(11):2330. doi: 10.3390/pharmaceutics14112330.
9
Efficacy of subthreshold micropulse laser combined with ranibizumab in the treatment of diabetic macular edema.亚阈值微脉冲激光联合雷珠单抗治疗糖尿病黄斑水肿的疗效。
Int Ophthalmol. 2022 Dec;42(12):3829-3836. doi: 10.1007/s10792-022-02403-5. Epub 2022 Jul 25.
10
Comparison of the 1-Year Visual and Anatomical Outcomes between Subthreshold Red (670 nm) and Yellow (577 nm) Micro-Pulse Laser Treatment for Diabetic Macular Edema.阈下红色(670纳米)与黄色(577纳米)微脉冲激光治疗糖尿病性黄斑水肿的1年视力和解剖学结果比较
Pharmaceuticals (Basel). 2021 Oct 28;14(11):1100. doi: 10.3390/ph14111100.